Clinical outcomes associated with kidney function changes in anticoagulated atrial fibrillation patients: An ancillary analysis from the BOREALIS trial.

ABSTRACT:

Background

Patients with atrial fibrillation (AF) and chronic kidney disease represent a high-risk group for thromboembolism and bleeding.

Aims

To explore the relationship between kidney function changes and outcomes of stroke/systemic embolism (SE), major bleeding and all-cause death in anticoagulated AF patients participating in the BOREALIS trial comparing efficacy and safety of once-weekly s.c. idrabiotaparinux to that of warfarin.

Methods

Changes in kidney function by estimated glomerular filtration rate (eGFR) were calculated using the Chronic Kidney Disease Epidemiology Collaboration equation in 2765 AF patients. Trial adjudicated outcomes were determined.

Results

After a mean follow-up of 394 days, in 94.4% of the included patients kidney function chang

SUBMITTER: Bai Y 

PROVIDER: S-EPMC7132193 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature